Microchip Biotech announced that the company's product, Theoloni capsules, obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials. Theoroni capsules are indicated for first-line treatment of patients with metastatic pancreatic duct adenocarcinoma in combination with PD-1 monoclonal antibody and chemotherapy. Theoroni is a novel chemical-structured small molecule class 1 original anti-tumor drug independently developed by the company. It has a multi-channel anti-tumor mechanism.

Zhitongcaijing · 4d ago
Microchip Biotech announced that the company's product, Theoloni capsules, obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials. Theoroni capsules are indicated for first-line treatment of patients with metastatic pancreatic duct adenocarcinoma in combination with PD-1 monoclonal antibody and chemotherapy. Theoroni is a novel chemical-structured small molecule class 1 original anti-tumor drug independently developed by the company. It has a multi-channel anti-tumor mechanism.